1. Home
  2. DMAC vs MYPS Comparison

DMAC vs MYPS Comparison

Compare DMAC & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • MYPS
  • Stock Information
  • Founded
  • DMAC 2000
  • MYPS 2011
  • Country
  • DMAC United States
  • MYPS United States
  • Employees
  • DMAC N/A
  • MYPS N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • MYPS EDP Services
  • Sector
  • DMAC Health Care
  • MYPS Technology
  • Exchange
  • DMAC Nasdaq
  • MYPS Nasdaq
  • Market Cap
  • DMAC 224.6M
  • MYPS 229.4M
  • IPO Year
  • DMAC N/A
  • MYPS N/A
  • Fundamental
  • Price
  • DMAC $5.80
  • MYPS $1.87
  • Analyst Decision
  • DMAC Strong Buy
  • MYPS Hold
  • Analyst Count
  • DMAC 3
  • MYPS 5
  • Target Price
  • DMAC $7.00
  • MYPS $3.17
  • AVG Volume (30 Days)
  • DMAC 100.7K
  • MYPS 230.2K
  • Earning Date
  • DMAC 03-18-2025
  • MYPS 03-10-2025
  • Dividend Yield
  • DMAC N/A
  • MYPS N/A
  • EPS Growth
  • DMAC N/A
  • MYPS N/A
  • EPS
  • DMAC N/A
  • MYPS N/A
  • Revenue
  • DMAC N/A
  • MYPS $298,759,000.00
  • Revenue This Year
  • DMAC N/A
  • MYPS N/A
  • Revenue Next Year
  • DMAC N/A
  • MYPS N/A
  • P/E Ratio
  • DMAC N/A
  • MYPS N/A
  • Revenue Growth
  • DMAC N/A
  • MYPS N/A
  • 52 Week Low
  • DMAC $2.14
  • MYPS $1.20
  • 52 Week High
  • DMAC $6.41
  • MYPS $3.04
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 58.22
  • MYPS 51.32
  • Support Level
  • DMAC $5.25
  • MYPS $1.66
  • Resistance Level
  • DMAC $5.85
  • MYPS $1.86
  • Average True Range (ATR)
  • DMAC 0.39
  • MYPS 0.10
  • MACD
  • DMAC 0.01
  • MYPS -0.01
  • Stochastic Oscillator
  • DMAC 73.02
  • MYPS 61.76

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

About MYPS PLAYSTUDIOS Inc.

PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore, and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.

Share on Social Networks: